RLMD — Relmada Therapeutics Share News
0.000.00%
Last trade - 00:00- $350.94m
- $133.21m
Brief: Relmada Therapeutics Q1 Net Income USD -17.5 Million
Relmada Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Relmada Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing
Brief: Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
Relmada Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Brief: Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB
U.S. STOCKS ON THE MOVE-Apollo, Hershey, RH
Relmada Therapeutics explores strategic options; shares up
Relmada discontinues late-stage trials for depression drug, explores sale (updated)
Relmada discontinues late-stage trials for depression drug, explores sale
Brief: Relmada Therapeutics To Discontinue The Reliance Ii And Relight Phase 3 Studies Of Rel-1017
U.S. RESEARCH ROUNDUP- Autozone, Costco Wholesale, Salesforce
U.S. STOCKS ON THE MOVE-Stoke Therapeutics, Foot Locker, Marvell
U.S. STOCKS ON THE MOVE-Nano Nuclear, JetBlue, Cross Country
U.S. STOCKS ON THE MOVE-Eli Lilly, GM, Dollar Tree
Relmada Therapeutics slumps as depression drug unlikely to meet main trial goal